Alloksys Life Sciences is a pioneering company in the field of alkaline phosphatase-based medical treatments for critical care patients.
Alloksys Life Sciences is a pioneering company in the field of alkaline phosphatase-based medical treatments for critical care patients.
“In the early 1990s, the potential for using alkaline phosphatase (RESCAP®) to detoxify bacterial toxins was discovered. We proposed that this enzyme could be a simple treatment for various diseases and medical applications. As more scientists and clinicians came to share this belief in its potential, We were motivated to continue developing RESCAP®. Today, clinicians, investors, and employees continue to be encouraged by the potential of RESCAP® due to the abundance of pre-clinical and clinical research publications and our positive interim phase 2b results with RESCAP®”
RESCAP® (rescuing alkaline phosphatase) is the proprietary name for our medication based on the enzyme alkaline phosphatase (AP), naturally present in the body and part of the innate immune system (‘first line of defence’).
RESCAP® is a therapeutic designed to expedite the recovery process for critical care patients. The use of RESCAP® has been shown to significantly reduce the time it takes for patients in the ICU to stabilize and to lower the occurrence of severe complications, thereby improving their chances of recovery.
RESCAP® intervention prevents inflammation
Therefore, RESCAP® restores the normal homeostasis and thus will accelerate recovery of patients in the ICU.
RESCAP® intervention prevents and restores leaky boundaries
RESCAP® intervention prevents ischemia-induced organ damage
RESCAP® is a therapeutic designed to expedite the recovery process for critical care patients. The use of RESCAP® has been shown to significantly reduce the time it takes for patients in the ICU to stabilize and to lower the occurrence of severe complications, thereby improving their chances of recovery.
RESCAP® intervention has the potential to prevent inflammation.
RESCAP® intervention has the potential to prevent and restore leaky boundaries
RESCAP® intervention has the potential to prevent ischemia-induced organ damage
Therefore, RESCAP® restores the normal homeostasis and thus will accelerate recovery of patients in the ICU.
The Alloksys team is committed to bringing RESCAP® to market and making it widely available for those who could benefit from it.
CEO
President
CSO
Medical Director
October 1, 2024. Alloksys anticipates that in the just started continuation of the APPIRED III study (a placebo-controlled combined phase IIb / III trial), with
July 1-2024. Alloksys anticipates that a treatment with RESCAP® reduces the immediate complications resulting from the kidney transplantation procedure and improves the long-term graft survival.
Wageningen, the Netherlands, 24 August 2023 – Alloksys Life Sciences, a clinical stage biotech company specializing in the development of critical care medicines, today announced
APPIRED III study is getting well on its way with 9 centres started with including patients. These centres are Singapore NUH, CZE Eindhoven, Jessa, Hasselt,
Alloksys Life Sciences is a pioneering company in the field of alkaline phosphatase-based medical treatments for critical care patients.
